The global Glucagon-like peptide-1 (GLP-1) analogues market is estimated to be valued at US$11.87 billion in 2023 and is expected to exhibit a CAGR of 1.12% over the forecast period 2023-2028, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
GLP-1 analogues are a type of medication used in the treatment of type 2 diabetes. These analogues mimic the effects of natural GLP-1, a hormone that helps regulate blood sugar levels. GLP-1 analogues offer several advantages, including lower risk of hypoglycemia, weight loss benefits, and improvement in cardiovascular outcomes. With the growing prevalence of diabetes worldwide, the demand for effective diabetes management medications such as GLP-1 analogues is on the rise.
Market Key Trends:
One key trend in the GLP-1 analogues market is the increasing adoption of injectable GLP-1 analogues over oral medications. Injectable GLP-1 analogues, such as Victoza and Trulicity, offer better glucose control and weight management compared to oral diabetic medications. These injectable formulations also provide greater convenience for patients as they are typically administered once a week. The preference for injectable GLP-1 analogues is driven by the desire for improved glycemic control and the need for long-acting formulations, which are better suited for patients with diabetes. This trend is expected to continue driving market growth for GLP-1 analogues in the coming years.
Porter’s Analysis
· Threat of new entrants: The threat of new entrants in the Glucagon-like peptide-1 (GLP-1) analogs market is moderate. While the market is highly specialized and requires significant research and development investments, potential new entrants may be enticed by the potential for high profit margins. However, established players in the market enjoy economies of scale and strong brand recognition, making it difficult for new entrants to gain a significant foothold.
· Bargaining power of buyers: The bargaining power of buyers in the GLP-1 analogs market is high. Buyers, including healthcare providers and patients, have a wide range of options to choose from, making them more price-sensitive. Moreover, the availability of generic versions of some GLP-1 analogs increases buyer power as it provides them with more affordable alternatives.
· Bargaining power of suppliers: The bargaining power of suppliers in the GLP-1 analogs market is relatively low. Pharmaceutical companies that develop GLP-1 analogs depend on a network of suppliers to source raw materials and ingredients. While these suppliers may have some bargaining power due to the specialized nature of the industry, the presence of multiple suppliers and the ability of manufacturers to switch suppliers reduces their overall power.
· Threat of new substitutes: The threat of new substitutes in the GLP-1 analogs market is low. GLP-1 analogs are a highly effective treatment for type 2 diabetes and offer unique benefits compared to other medications. Additionally, the extensive research and regulatory requirements involved in developing substitute treatments make it challenging for alternatives to enter the market.
· Competitive rivalry: The competitive rivalry in the GLP-1 analogs market is intense. The market is dominated by a few major players, including Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca plc, GlaxoSmithKline plc, and F. Hoffmann-La Roche Ltd. These companies constantly strive to gain market share through product innovation, patent protection, and aggressive marketing strategies. As a result, there is high competition among these key players, leading to intense rivalry in the market.
Key Takeaways
The global GLP-1 Analogs Market Size is expected to witness high growth, exhibiting a CAGR of 1.12% over the forecast period of 2023-2028. This growth can be attributed to increasing prevalence of type 2 diabetes worldwide, as well as the effectiveness of GLP-1 analogs in managing the condition. Rising awareness about the benefits of GLP-1 analogs among healthcare providers and patients is also driving market growth.
In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the GLP-1 analogs market. This can be attributed to the high prevalence of type 2 diabetes in the region, as well as the presence of well-established healthcare infrastructure. Additionally, increased focus on research and development activities and the launch of new GLP-1 analog products further drive the growth of the market in North America.
Key players operating in the GLP-1 analogs market include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca plc, GlaxoSmithKline plc, and F. Hoffmann-La Roche Ltd. These companies are at the forefront of product innovation and have a strong market presence. Their extensive distribution networks and strategic collaborations contribute to their market dominance in the GLP-1 analogs segment.
In conclusion, the global GLP-1 analogs market is set to experience significant growth in the coming years. Factors such as the increasing prevalence of type 2 diabetes, rising awareness about the benefits of GL .
